SCHEMBL15716348

SCHEMBL15716348

Cc1nc(-c2ccccc2)c(N)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK13 O15264 1/20 0.54
▸ MAPK12 P53778 1/20 0.54
▸ MAPK11 Q15759 1/20 0.54
▸ MAPK14 Q16539 1/20 0.54
▸ NR4A2 P43354 1/20 0.48
▸ PTGS2 P35354 2/20 0.47
▸ KMT2A Q03164 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ TDO2 P48775 1/20 0.43
▸ PDE10A Q9Y233 1/20 0.43
▸ ADORA2A P29274 4/20 0.42
▸ ADORA1 P30542 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5214925 0.79 MAPK13 (0.58) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL5154427 0.79 NR4A2 (0.68) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL4741741 0.78 IKBKB (0.56) NR4A2KMT2AKDM4EALDH1A1HPGD
SCHEMBL2091239 0.78 MAPK13 (0.83) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL31469380 0.76 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL5154162 0.76 NR4A2 (0.48) NR4A2KMT2AKDM4EALDH1A1HPGD
SCHEMBL5538991 0.76 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL5008393 0.76 MAPK13 (0.50) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL10264165 0.73 MAPK13 (0.51) MAPK13MAPK12MAPK11MAPK14NR4A2
SCHEMBL26051044 0.73 MAPK13 (0.51) MAPK13MAPK12MAPK11MAPK14NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981959-B2 Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-05-29 — — US disclosed
US-20160280702-A1 THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-09-29 — — US disclosed
WO-2014078322-A1 THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280702-A1 THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS TK1, MUSK, CHUK MAPK13 508/4885MAPK12 431/4885MAPK11 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback